Panel Discussion: Addressing the Shortcomings of Developing NSCLC-Targeted Therapies
Time: 8:50 am
day: Day One
- Patient population response differences and how to overcome these
- What design elements are most optimal to achieve clinical benefit?
- The push to early disease: what will this entail?
- How can the mechanism of action be predicted for each patient and thus inform dosing strategies?